Changes in surgicaL behaviOrs dUring the CoviD-19 pandemic. The SICE CLOUD19 StudyCoviD-19 전염병 동안 수술 행동의 변화. SICE CLOUD19 연구Original Article Published on 2021-03-032022-09-12 Journal: Updates in surgery [Category] MERS, SARS, 진단, [키워드] activity AEGIS affecting analyzed cause change changed Community completion COVID-19 COVID-19 disease COVID-19 pandemic database effective Elective surgery Emergency Emergency surgery general surgery Health hospital impacted indicate Italian Laparoscopic surgery laparoscopy less make up Ministry of Health modify MOST not performed offer pandemic Patient patients performed Phase I reduce reduction in Registered reported Responder Result safety profile SARS-CoV2 smoke Society Spread supplementary material surgeon surgery surgical surgical operation survey virus [DOI] 10.1007/s13304-021-01010-w PMC 바로가기 [Article Type] Original Article
DPP-4 inhibition and COVID-19: From initial concerns to recent expectationsDPP-4 억제와 코로나19: 초기 우려에서 최근 기대까지Review Published on 2021-03-012022-08-31 Journal: Diabetes & metabolism [Category] SARS, 바이오마커, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Admission Admissions Anti-inflammatory effects Antigen appear benefit best binding domain CD26 Clinical outcome clinical outcomes Clinical practice coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient cytokine Cytokine storm Cytokine storms diabete diabetes dipeptidyl peptidase domain enzyme expressed form functional functions Gliptin heterogeneous high affinity Host Hypothesis hypothetical Immune cell immune cells Incretin infections Inflammation inherent inhibitor initial intensive care unit intensive care units limitation management Mortality observational studies outcome Patient patients with COVID-19 positive progression Randomized controlled trial Randomized controlled trials receptor recommendation reductions in regulate respiratory responsible retrospective risk Safe safety profile SARS-CoV-2 severe acute respiratory syndrome Coronavirus significant reductions susceptibility susceptibility to infections T-cell the disease type 2 diabete Type 2 diabetes mellitus virus while [DOI] 10.1016/j.diabet.2020.11.005 PMC 바로가기 [Article Type] Review
Exploring existing drugs: proposing potential compounds in the treatment of COVID-19Research article Published on 2021-02-262022-10-05 Journal: Heliyon [Category] 신약개발, 유전자 메커니즘, 치료법, 치료제, [키워드] ACE2 addressed alignment approved basic candidate characterized Compound confirmed case conserved conserved region COVID-19 COVID-19 epidemic COVID-19 situation database death docking drug Drug repurposing drugs effective evolutionary relationship identify in vitro in vivo inhibit International Johns Hopkins University Lopinavir microorganism Molecular modeling molecular target much higher Off Pacritinib Phylogenetic tree public health emergency Region Remdesivir reported researcher Safe safety profile SARS-CoV-2 SARS-COV-2 infection searched Seven similarity South Asian strain TMPRSS2 Treatment virus viruses was used were used World Health Organization [DOI] 10.1016/j.heliyon.2021.e06284 [Article Type] Research article
A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive ReviewPharmacology Published on 2021-02-262022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] acute viral respiratory distress syndrome addition antiviral agent approach candidate Cell therapy clinical trial commenced Comprehensive contagious CoV COVID-19 COVID-19 disease COVID-19 outbreak distress DNA drug effective Efficacy epidemiological Epidemiology global healthcare HCQ IL-6 inactivated include Infection information inhibit insight International Lopinavir/ritonavir magnitude medication mRNA novel Open-label overexpression pandemic Pandemics peptide phosphate PLPro Pneumonia positive Potential prophylactic strategy protease quarantine RdRP Research researcher review robust Safe safety profile SARS-CoV-2 SARS-COV-2 infection selected siltuximab Spread STEM sub-unit vaccines therapeutic therapeutic strategy tolerable Treatment Vaccine vaccine candidate Vaccines viral membrane virion virulent [DOI] 10.3389/fphar.2020.590154 PMC 바로가기 [Article Type] Pharmacology
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical PeculiaritiesReview Published on 2021-02-252022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] administration Antiviral Antiviral effect approved benefit chloroquine/hydroxychloroquine Clinical improvement COVID-19 death dietary supplements drug Drug repurposing drugs effective Efficacy heparin high risk highlight Hydroxychloroquine insight Lopinavir/ritonavir Mortality Older Ozone patients pharmaceutical pharmaceutical formulations pharmacokinetic phosphodiesterase inhibitors potential treatments reduced risk Regulatory Remdesivir reported repurposing Safe safety profile Severe respiratory distress syndrome tested treatments for COVID-19 [DOI] 10.3390/pharmaceutics13030302 PMC 바로가기 [Article Type] Review
Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 PandemicPediatrics Published on 2021-02-232022-10-31 Journal: Frontiers in Pediatrics [Category] COVID-19, [키워드] Anakinra Analysis biochemical children clinical condition clinical feature Controlled clinical trial COVID-19 COVID-19 outbreak criteria Cytokine storm syndrome demonstrated Effectiveness form IL-1 IL-1 receptor antagonist Inflammatory inflammatory disease Intravenous immunoglobulin Kawasaki Kawasaki disease MIS-C MISC-C myocarditis Patient patients PIMS-TS reported safety profile SARS-CoV-2 SARS-COV-2 infection Shock suggested syndrome systemic glucocorticoid the patient Therapeutic approach triggered with COVID-19 [DOI] 10.3389/fped.2020.624248 PMC 바로가기 [Article Type] Pediatrics
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in RussiarAd26 및 rAd5 벡터 기반 이종 프라임-부스트 COVID-19 백신의 안전성 및 효능: 러시아의 무작위 대조 3상 시험 중간 분석Clinical Trial Published on 2021-02-202022-09-12 Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, [키워드] 95% CI Administered adverse event age Analysis assigned available data case report form Cellular immune response city clinical trials COVID-19 database death Department Direct dose double-blind Efficacy Efficacy and safety enrolment events excluded first dose full-length SARS-CoV-2 Gam-COVID-Vac glycoprotein Heterologous heterologous prime-boost hospital humoral IgG and IgM independent Infectious disease interim analysis intramuscularly Investment large cohort MOST participant Participants PCR-confirmed COVID-19 phase 3 trial Placebo placebo-controlled Primary outcome primary outcome analysis proportion protocol randomised randomised controlled Randomly receive receiving recombinant adenovirus Registered reported Russia Safety safety profile SARS-CoV-2 PCR second dose Serious Adverse Event Stratification the placebo group the vaccine Trial vaccination Vaccine vector were assessed [DOI] 10.1016/S0140-6736(21)00234-8 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targetsSARS-CoV-2 조기 감염 시그니처는 잠재적인 주요 감염 메커니즘 및 약물 표적 식별Research Article Published on 2021-02-182022-09-10 Journal: BMC Genomics [Category] MERS, 신약개발, 유전자 메커니즘, [키워드] addition antidepressants association atorvastatin BALF BALF cells bimodal biopsies Bronchoalveolar lavage fluid Bronchoalveolar lavage fluid cells candidate Candidates caused Cell characterized COVID-19 COVID-19 disease COVID-19 disease severity COVID-19 outbreak COVID-19 treatments cultured cell cultured cells database dataset deaths Differential gene expression disease drug drug target early infection effective Efficacy expression profile Gene Expression gene signature HDAC healthy healthy and infected patients highlighting ibuprofen identify IFIT2 Immune cell immune cells infected patient infected with SARS-CoV-2 Infection infection mechanism inhibitors investigated ketoconazole lung lung biopsies mechanism moderate mononuclear cell mononuclear cells Mortality NFKBIA PBMC PBMCs Peripheral blood Peripheral blood mononuclear cells PPP1R15A Previous studies previous study public health Result robust safety profile SARS-CoV-2 SARS-CoV-2 gene expression signature SARS-COV-2 infection Sequencing severely infected patient severely infected patients severity shown signature single-cell supplementary material the disease the SARS-CoV-2 therapy TNFAIP3 transcriptional activity treating SARS-CoV-2 infection Treatment Vaccine [DOI] 10.1186/s12864-021-07433-4 PMC 바로가기 [Article Type] Research Article
A sprayable Acid-Oxidizing solution containing hypochlorous acid (AOS2020) efficiently and safely inactivates SARS-Cov-2: a new potential solution for upper respiratory tract hygieneMiscellaneous Published on 2021-02-112022-10-31 Journal: European archives of oto-rhino-laryngology : offic [Category] COVID-19, MERS, SARS, [키워드] Acid-Oxidizing solution (AOS2020) blocked coronavirus COVID-19 pandemic early stage Efficacy evaluate Guidance HClO highest hygiene Hypochlorous acid (HClO) in vitro indicate initial International intranasal mortality rates nasal National oral mucosa Potential treatment reduce reduced respiratory tract Result safety profile SARS-CoV-2 the disease Tolerability Transmission upper upper respiratory upper respiratory tract Viral load virucidal virus [DOI] 10.1007/s00405-021-06644-5 PMC 바로가기 [Article Type] Miscellaneous
Plasma Concentrations and Safety of Lopinavir/Ritonavir in COVID-19 PatientsCOVID-19 환자에서 로피나비르/리토나비르의 혈장 농도 및 안전성Article Published on 2021-02-012022-09-11 Journal: Therapeutic drug monitoring [Category] 치료제, [키워드] absence Adverse drug reaction Adverse drug reactions antiviral activity average caution Concentration COVID-19 COVID-19 patient disorders dosage drug reaction Efficacy expected HIV HIV treatment in vivo increase in Inflammation Inflammatory interquartile lAbel limit Lopinavir Lopinavir/ritonavir moderate-to-severe COVID-19 Occurrence off-label off-label use one patient Patient plasma concentration plasma concentrations Previous studies reduced reported required Retrospective study Ritonavir Safety safety profile SARS-CoV-2 significantly suggested treated Treatment treatment for COVID-19 [DOI] 10.1097/FTD.0000000000000838 PMC 바로가기 [Article Type] Article